LONDON (ShareCast) - Shares in Oxford BioMedica jumped after French and US regulators gave their approval for the biopharmaceutical group to resume recruitment for trials of three potential eye medicines it is developing with France’s Sanofi.

The UK company voluntarily paused recruitment into three clinical studies as a precautionary measure whilst it investigated the detection of a potential impurity in its clinical trial material.

It said it had since identified the impurity as highly fragmented DNA derived from foetal bovine serum, the most widely-used growth supplement for cell culture media. It said as a result of these findings it was convinced of the safety of its products and said no safety concerns relating to any of the ocular products had been identified in any pre-clinical and clinical data generated to date.

Oxford BioMedica submitted a comprehensive data package to the US Food and Drug Administration and the French regulatory agency ANSM and has now received agreement from both agencies for it to resume recruitment in its ocular clinical trials using the existing clinical trial material.

Shares in Oxford BioMedica were up 8.6% at 2.5p at 15:32 on Thursday.

TB

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE